Sector News

Pfizer looks to rebuild abandoned vaccines biz in China

November 2, 2016
Life sciences

More than a year after pulling its vaccines out of one of the world’s most challenging but lucrative drug markets, Pfizer has moved back into China with a nod for big-selling Prevenar 13.

With that green light in hand for its pneumococcal disease blocker, a key contributor to Pfizer’s overall business, the company is working on a launch timeline, a spokesperson told FiercePharma.

Pfizer didn’t indicate what level of sales the new market could bring, but even a small boost could help the shot, sold in the U.S. as Prevnar 13. After boasting double-digit growth for some time, the shot has struggled in recent quarters; for Q3, sales fell 3% to $1.54 billion. In September, analysts with EvaluatePharma predicted Prevnar 13 would slip 1% yearly through 2022.

The new approval in China covers Prevenar 13 in children aged six weeks to 15 months. Approximately 30,000 children in that age range die in China from pneumococcal diseases each year.

The Chinese government nod is a turnabout for Pfizer in that vaccines market, which the drug giant decided to abandon last year. Pfizer moved to pull its vaccines from the country after the import license for Prevenar 13’s predecessor wasn’t renewed. That decision affected 200 employees in vaccine sales, according to reports at the time.

Now, Pfizer will be staffing back up for the new launch. A Pfizer spokesperson didn’t specify staffing numbers, but said the company looks “forward to building a strong vaccines business in China, and we aim to attract the most qualified talent.”

Prevenar 13’s approval in China could serve as a much-needed boost for a franchise that has struggled in recent quarters after posting enormous growth last year. The shot brought $6.24 billion to Pfizer’s top line in 2015.

In 2014, a key CDC committee in the U.S. recommended the vaccine for adults over 65, creating an opportunity for a $2 billion sales boost. But because of a “high initial capture rate,” Pfizer now says the franchise is suffering from an “expected decline.”

By Eric Sagonowsky

Source: Fierce Pharma

comments closed

Related News

November 28, 2021

Founder-led biotech is making space for ideas—and diverse leaders—where it didn’t exist before

Life sciences

Decades ago, the founder-led biotech was rare and considered the tougher path to follow. Now there is a trend of founder-led biotechs that have risen in prominence in recent years, going from startup to well known with lightning speed. Scientists-turned C-suite occupants know their technology inside out. They’ve got credibility both at the bench working with their research teams and in the boardrooms selling their future products.

November 28, 2021

Pfizer to become $100B behemoth next year thanks to COVID-19 drug and vaccine: analyst

Life sciences

Pfizer’s revenue could reach $101.3 billion in 2022, with major contributions coming from the company’s BioNTech-partnered COVID vaccine and an antiviral therapeutic that has shown stellar clinical data, SVB Leerink analyst Geoffrey Porges projected in a Monday note to clients.

November 28, 2021

GlaxoSmithKline takes aim at sick pay access inequities with microgrant program and new campaign

Life sciences

In a survey commissioned by GlaxoSmithKline’s consumer health division of 2,000 working people in the U.S., almost 70% admitted to clocking in while sick, often because they couldn’t afford to lose a day’s pay. Black and Latina women were 10% more likely than white women to shun taking sick time for fear of fallout from their boss, according to the company’s 2021 Temperature Check Report.

Send this to a friend